This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Inogen (INGN)

Tipranks - Tipranks - Fri Nov 7, 2025

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Natera (NTRA – Research Report), Inogen (INGN – Research Report) and Stevanato Group (STVN – Research Report) with bullish sentiments.

Meet Your ETF AI Analyst

Natera (NTRA)

In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on Natera. The company’s shares closed last Thursday at $198.44.

According to TipRanks.com, Bonello is a 5-star analyst with an average return of 36.3% and a 68.2% success rate. Bonello covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, Myriad Genetics, and Guardant Health. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Natera with a $205.50 average price target, representing a 3.4% upside. In a report issued on October 29, Canaccord Genuity also maintained a Buy rating on the stock with a $200.00 price target.

See the top stocks recommended by analysts >>

Inogen (INGN)

B. Riley Securities analyst Anderson Schock reiterated a Buy rating on Inogen yesterday and set a price target of $14.00. The company’s shares closed last Thursday at $7.32, close to its 52-week low of $6.14.

According to TipRanks.com, Schock is a 4-star analyst with an average return of 37.0% and a 90.0% success rate. Schock covers the Healthcare sector, focusing on stocks such as InfuSystem Holdings, Varex Imaging, and Exagen. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inogen with a $11.00 average price target, implying a 50.1% upside from current levels. In a report released yesterday, Needham also reiterated a Buy rating on the stock with a $12.00 price target.

Stevanato Group (STVN)

In a report released today, Matt Larew from William Blair maintained a Buy rating on Stevanato Group. The company’s shares closed last Thursday at $24.38.

According to TipRanks.com, Larew is a 1-star analyst with an average return of -0.9% and a 47.9% success rate. Larew covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, West Pharmaceutical Services, and Ginkgo Bioworks Holdings. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Stevanato Group with a $27.00 average price target.

Read More on NTRA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).